A new study reveals that off-the-shelf CD19-targeted CAR-T cell therapy effectively treats relapsed systemic lupus erythematosus (SLE), achieving remission and kidney recovery. Discover how this innovative approach may revolutionize autoimmune disease treatment.
Recently, a clinical study on “Targeted CD19 Chimeric Antigen Receptor T-Cell Therapy for Refractory Pediatric Systemic Lupus Erythematosus” has been successfully completed with the 20th patient undergoing CAR-T cell infusion.
Dr. Xu Huji becomes a Nature 2024 Top 10 Scientist for developing the world’s first universal CAR-T therapy for autoimmune diseases—marking a breakthrough in low-cost, scalable immunotherapy.
Breakthrough study in China shows off-the-shelf CAR-T therapy can reverse severe autoimmune disease, offering faster, safer, and more affordable treatment.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.